April 3, 2023

Structural and functional brain MRI of patients before and after neflamapimod treatment shows increased NbM volume and increased functional dynamic connectivity between NbM and deep grey matter BOSTON, MA – April 3, 2023 – EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced the oral presentation by academic […]

March 30, 2023

Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging Combined company expected to have a cash runway through Phase 2b […]

January 18, 2023

BOSTON, MA, January 18th, 2022 /PRNewswire/ – EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) awarded the Company a grant of $21 million to support a 160-patient phase 2b study of neflamapimod in […]

December 2, 2022

In structural MRI images obtained before and after 12 weeks treatment, neflamapimod significantly increased the volume of the Nucleus Basalis of Meynert, the major nucleus of cholinergic neurons in the basal forebrain, in patients with early AD BOSTON, MA, December 2nd, 2022 /PRNewswire/ – EIP Pharma Inc., a private clinical stage biopharmaceutical company focused on […]

September 21, 2022

  EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications – Neflamapimod demonstrates that it reverses the neurodegenerative process in the basal forebrain cholinergic system in animal models – – Phase 2a data in Dementia with Lewy Bodies show positive effects of neflamapimod on […]

November 10, 2021

EIP Pharma announces that final results of the AscenD-LB phase 2 clinical study demonstrates neflamapimod has disease-modifying potential in dementia with Lewy Bodies   Results presented at 14th Clinical Trials in Alzheimer’s Disease (CTAD) meeting in Boston   Neflamapimod treatment led to significant improvement relative to placebo in cognition, motor function, and cognition & function […]

November 4, 2021

Final results of the AscenD-LB clinical study informs on disease-modifying potential of neflamapimod in dementia with Lewy bodies Presentations at 14th Clinical Trials in Alzheimer’s Disease Meeting, November 9-12, 2021 BOSTON, Nov. 4, 2021 /PRNewswire/ — EIP Pharma Inc., a clinical-stage pharma company focused on the development of disease-modifying treatments for dementia and neurodegenerative diseases announces that the […]

As an internationally recognized dementia clinical expert, Dr. Sabbagh brings deep knowledge of disease, patient management and clinical trial experience BOSTON, Nov. 4, 2021 /PRNewswire/ — EIP Pharma Inc., a clinical-stage pharma company focused on the development of disease-modifying treatments for dementia and neurodegenerative diseases announces the appointment of Dr. Marwan Sabbagh as non-executive director to its Board of Directors […]

December 16, 2020

Administration of neflamapimod during the subacute phase after transient ischemia induced stroke in rats promoted functional recovery  Associated increased levels of brain-derived neurotrophic factor (BDNF) suggest the effects were mediated by increasing synaptic plasticity Boston, Mass., December 16, 2020 – EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, announced today the scientific publication of preclinical […]

November 7, 2020

 Results of AscenD-LB Phase 2 clinical study demonstrate proof-of-concept for neflamapimod as a treatment for dementia with Lewy bodies (DLB)  Supports advancement of neflamapimod to late stage development as a treatment to improve cognition in patients with DLB Boston, Mass., November 7, 2020 – EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today provided the […]

October 6, 2020

AscenD-LB study met primary objective of improving cognition as assessed by the Neuropsychological Test Battery Full results to be presented during late-breaking session at Clinical Trials in Alzheimer’s Disease (CTAD) meeting  Boston, Mass., October 6, 2020 – EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that the Phase 2 AscenD-LB study in patients […]

December 5, 2019

Results demonstrate target engagement and proof-of-mechanism Boston, Mass., December 5, 2019 – EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that the efficacy and safety data from the REVERSE-SD clinical study were presented at the Clinical Trials in Alzheimer’s Disease (CTAD) meeting in San Diego by the principal investigator of the study, Professor […]

November 7, 2019

Results demonstrate target engagement and proof-of-mechanism Boston, Mass., November 7, 2019 – EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that the REVERSE-SD study of neflamapimod in early-stage Alzheimer’s disease met its secondary objectives of target engagement and proof-of-mechanism demonstrating statistically significant reductions relative to placebo in cerebrospinal fluid (CSF) levels of phospho-tau […]

Phase 2 clinical trial of neflamapimod in patients with mild-to-moderate DLB currently enrolling patients in the U.S. and the Netherlands Fast Track designation facilitates development of new therapies that treat serious conditions and fulfill an unmet medical need Boston, Mass., November 7, 2019 – EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that […]

August 1, 2019

EIP Pharma, Inc., a CNS-focused therapeutics company, today announced that company management will present at the Canaccord Genuity 39th Annual Growth Conference on Thursday, August 8, 2019, at 12:00 p.m. ET in Boston, MA.

July 17, 2019

Presentations at Late Breaker Session at Alzheimer’s Association International Conference (AAIC) 2019 Cambridge, Mass., July 17, 2019 – EIP Pharma, Inc., a CNS-focused therapeutics company, today announced that new preclinical data regarding neflamapimod were presented at the AAIC 2019 scientific meeting in Los Angeles, CA (July 14-18, 2019). “The findings add to the growing body […]

July 12, 2019

The primary objective of the study is to determine whether neflamapimod, a brain-penetrant, oral small molecule that inhibits the enzyme p38 alpha, can reverse the hippocampal synaptic dysfunction associated with DLB. 

July 9, 2019

EIP Pharma, Inc., a CNS-focused therapeutics company, today announced the initiation of a new Phase 2 proof-of-concept study evaluating neflamapimod as a treatment for the cognitive dysfunction associated with Huntington’s disease

July 8, 2019

EIP Pharma, Inc. a CNS-focused therapeutics company, today announced that it has expanded its leadership team with the appointment of Noel Donnelly as CFO. Mr. Donnelly joins EIP Pharma from Takeda Pharmaceuticals where he led a group focused on strategy and operations.

June 7, 2019

CAMBRIDGE, Mass., June 7, 2019 /PRNewswire/ — EIP Pharma, Inc., a CNS-focused therapeutics company, announced today that the Company will host a key opinion leader (KOL) breakfast briefing focused on the potential of neflamapimod in Alzheimer’s disease and Dementia with Lewy bodies on Friday, June 21st, 2019 at 8:00 a.m. ET in New York City. The event will feature guest speakers Steven […]

May 31, 2019

CAMBRIDGE, Mass., May 31, 2019 /PRNewswire/ — EIP Pharma, Inc., a CNS-focused therapeutics company, announced today that company management will present at two investor conferences in June. Jefferies 2019 Healthcare Conference Date: Friday, June 7th, 2019 Time: 9:00 a.m. ETLocation: New York, NY JMP Securities Life Sciences Conference Date: Thursday, June 20th, 2019 Time: 1:00 p.m. ETLocation: New York, NY A live audio webcast of both presentations […]

April 15, 2019

CAMBRIDGE, Mass., April 15, 2019 /PRNewswire/ — EIP Pharma, a CNS-focused therapeutics company, announced today the successful completion of $11.2 million in new private funding to explore the use of the investigational drug neflamapimod as a treatment for dementia with Lewy bodies and for the cognitive deficits in Huntington’sdisease. Phase 2 clinical studies in these new disease indications for neflamapimod are […]

February 11, 2019

CAMBRIDGE, Mass., February 11, 2019 — EIP Pharma, Inc., a CNS-focused therapeutics company, announced today that company management will present at the BIO CEO Investor Conference. The presentation will take place at 10:00 a.m. ET on February 12, 2019 in New York City. A live audio webcast of the event will be available on the […]

December 13, 2018

CAMBRIDGE, Mass., Dec 13, 2018 /PRNewswire/ — EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, announced today that it has fully enrolled the REVERSE-SD study, a placebo controlled, Phase 2b trial of the investigational drug neflamapimod in patients with Early Alzheimer’s disease. The Phase 2b trial is being conducted in the United States, United Kingdom, Netherlands, Denmark and the Czech Republic. Neflamapimod is a brain-penetrant oral small […]

October 24, 2018

Phase 2b study (REVERSE-SD) of neflamapimod in Early Alzheimer’s disease more than 50 percent enrolled

May 16, 2018

Proceeds to Support Continued Development of Neflamapimod for Alzheimer’s Disease

March 7, 2018

Phase 2a Results Published in Annals of Clinical and Translational Neurology Demonstrate Statistically Significant Improvement in Episodic Memory Function in Patients with Alzheimer’s Disease

Company Initiates Phase 2b (REVERSE-SD) Confirmatory Study with Neflamapimod

July 19, 2017

Neflamapimod reverses critical AD-related physiologic defect in human in vitro model system

July 18, 2017

Evidence that neflamapimod improves episodic memory function in patients with Early Alzheimer’s disease

November 8, 2016

CAMBRIDGE, Mass., Dec. 8, 2016 /PRNewswire/ — EIP Pharma, LLC (www.eippharma.com) today announced that it has obtained proof-of-mechanism for neflamapimod (previously code named VX-745), with the results of two recently completed Phase 2a clinical trials that demonstrated significant Alzheimer’s disease relevant pharmacological activity.  The findings from Study 302 (12-week treatment) and Study 303 (6-week treatment) are the subject […]

September 28, 2016

Patents provide broad coverage for administering VX-745 to treat Alzheimer’s disease and/or promote recovery after acute ischemic stroke

December 16, 2015

CAMBRIDGE, Mass., Dec. 16, 2015 /PRNewswire/ — EIP Pharma LLC today announced the publication in the Journal of Alzheimer’s Disease of an article entitled “Selective brain-targeted antagonism of p38 MAPK alpha reduces hippocampal IL-1 beta levels and improves Morris-Water-Maze Performance in Aged Rats,” which demonstrates pro-cognitive effects of VX-745 for the first time. “These results demonstrate the potential of p38 MAPK […]

June 3, 2015

First-ever human clinical studies designed to assess the effects of selective p38 alpha kinase inhibition on brain amyloid plaque load and inflammation in patients with Mild Cognitive Impairment (MCI) due to AD or mild AD